Last reviewed · How we verify
Intraarticular injection of WJMSC
Intraarticular injection of WJMSC is a Biologic drug developed by Medical University of Warsaw. It is currently in Phase 1 development.
At a glance
| Generic name | Intraarticular injection of WJMSC |
|---|---|
| Sponsor | Medical University of Warsaw |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis (PHASE1)
- Wharton's Jelly-derived Mesenchymal Stem Cells in Osteoarthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraarticular injection of WJMSC CI brief — competitive landscape report
- Intraarticular injection of WJMSC updates RSS · CI watch RSS
- Medical University of Warsaw portfolio CI
Frequently asked questions about Intraarticular injection of WJMSC
What is Intraarticular injection of WJMSC?
Intraarticular injection of WJMSC is a Biologic drug developed by Medical University of Warsaw.
Who makes Intraarticular injection of WJMSC?
Intraarticular injection of WJMSC is developed by Medical University of Warsaw (see full Medical University of Warsaw pipeline at /company/medical-university-of-warsaw).
What development phase is Intraarticular injection of WJMSC in?
Intraarticular injection of WJMSC is in Phase 1.
Related
- Manufacturer: Medical University of Warsaw — full pipeline